Study shows inhaled insulin promising in type 1 diabetes, reaching target A1c 30% of the time vs 17% with usual care in INHALE-3 trial.
A study presented at the American Diabetes Association's 84th Scientific Sessions shows promising results for inhaled insulin as a potential treatment for type 1 diabetes. The INHALE-3 trial compared the use of inhaled insulin plus insulin degludec with usual care, demonstrating that patients using inhaled insulin reached the target A1c (less than 7%) 30% of the time, compared to 17% with usual care. More than 50% of participants expressed interest in continuing to use Afrezza®.
June 22, 2024
5 Articles